Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23347862 | 0.94 | USP2 (0.41) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL21316779 | 0.91 | USP2 (0.43) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL22001602 | 0.89 | USP2 (0.42) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL408142 | 0.85 | ALDH1A1 (0.51) | USP2POLBALDH1A1HTTUSP30 | |
| SCHEMBL408989 | 0.85 | USP30 (0.54) | ALDH1A1HTR7HTR1AUSP30RAB9A | |
| SCHEMBL409337 | 0.84 | MAPK1 (0.48) | ALDH1A1USP30RAB9AMCHR1TSHR | |
| SCHEMBL408161 | 0.84 | MCHR1 (0.46) | POLBALDH1A1USP30ERN1MCHR1 | |
| SCHEMBL16209774 | 0.84 | HTR7 (0.47) | USP2POLBALDH1A1HTR7HTR1A | |
| SCHEMBL409810 | 0.83 | MCHR1 (0.50) | POLBALDH1A1SSTR5MAPK10MCHR1 | |
| SCHEMBL14655016 | 0.83 | USP2 (0.45) | USP2POLBALDH1A1HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10398721-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
| US-9862946-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9833468-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170198287-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-07-13 | — | — | US | disclosed |
| US-9326992-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160102307-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-9161948-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9066967-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024821-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | USP2 834/4885POLB 208/4885ALDH1A1 2803/4885 |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | USP2 834/4885POLB 208/4885ALDH1A1 2803/4885 |
| US-10398721-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | LMNA, LMNB2, LMNB1 | USP2 4045/4885POLB 54/4885ALDH1A1 4254/4885 |
| US-20160102307-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | USP2 4607/4885POLB 145/4885ALDH1A1 4394/4885 |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | NSUN2, UPF1, RTCB | USP2 834/4885POLB 208/4885ALDH1A1 2803/4885 |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | USP2 834/4885POLB 208/4885ALDH1A1 2803/4885 |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNA, LMNB2, LMNB1 | USP2 4045/4885POLB 54/4885ALDH1A1 4254/4885 |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | USP2 834/4885POLB 208/4885ALDH1A1 2803/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | USP2 2844/4885POLB 202/4885ALDH1A1 3700/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | USP2 2844/4885POLB 202/4885ALDH1A1 3700/4885 |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | USP2 4607/4885POLB 145/4885ALDH1A1 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.